The progressive decline in testosterone level has been demonstrated in both cross-sectional and longitudinal studies, and overall at least 25% of men over the age of 70 years meet laboratory criteria for hypogonadism (i.e., testosterone deficiency). Such age-associated HPG hypofunctioning, which has been termed 'andropause', is thought to be responsible for a variety of symptoms experienced by elderly men, including sexual dysfunction and depression. Although, it has been difficult to establish correlations between 'andropausal' symptoms and plasma testosterone levels, there is some evidence that testosterone replacement leads to improvement in muscle strength, bone mineral density, and erectile dysfunction. There is little evidence of a link between HPG-axis dysfunction and depressive illness, and exogenous androgens have not been consistently shown to be antidepressant. This article reviews the relationship between androgens and depression in aging men.
Introduction
Male hypothalamic-pituitary-gonada (HPG) function declines progressively with age and a substantial proportion of men older than age of 50 years have testosterone levels below the threshold values used to define testosterone deficiency in younger men. 1 Mild testosterone deficiency in middle-aged and elderly men can, therefore, be considered physiological (i.e., a para-aging phenomenon) or pathological (i.e., a deficit state). Since age-adjusted norms are not used, it is treated as pathological. Yet, even if it is considered physiological, this 'normative' decline may be clinically significant, as is the case with the age-associated decline in female gonadal hormones.
Whether the age-dependent decline in androgen levels leads to health problems in men is being debated vigorously. [2] [3] [4] Some investigators argue that age-associated testosterone deficiency, or 'andropause,' is responsible for many of the typical signs of male aging, such as erectile dysfunction (ED), decreased lean body mass, skin alterations, osteoporosis, and increased visceral fat; as well as for neuropsychiatric problems, such as fatigue, loss of libido, depression, irritability, insomnia, and memory impairment. 4 Furthermore, the application of a testosterone replacement strategy for older men with low or low-normal testosterone levels is thought by some investigators to be especially promising for reversing such presumed 'andropausal' sequelae. 5 Yet, it has not only been difficult to correlate hormone levels with these age-related phenomena, 3, 4 but testosterone replacement in elderly men is not especially effective in reversing these symptoms. 6, 7 For example, although testosterone replacement in elderly men has been demonstrated to enhance upper limb strength 8, 9 and mass, 7 improve bone mineral density, 6 increase hematocrit, 10 and reduce leptin levels (an effect that may improve visceral adiposity), 8 such effects are apparently weak and likely of no clinical consequence. There are few testosterone replacement studies in which psychiatric symptoms of age-related hypogonadism have been considered. Here, we will focus on psychiatric aspects of male HPG-axis hypofunctioning, and consider the relationship between testosterone and depressive illness.
HPG-axis physiology
The gonads and adrenals secrete several 'male' sex hormones, called androgens. All are steroid hormones -that is, derived from cholesterol and containing a basic skeleton of four fused carbon rings. Testosterone is the most potent and abundant androgen. Gonadotropin-releasing hormone (GnRH) from the hypothalamus promotes anterior pituitary release of luteinizing hormone (LH) and folliclestimulating hormone (FSH). LH stimulates the interstitial cells of Leydig in the testes to synthesize and secrete testosterone. Testosterone secretion occurs in pulsatile bursts, about six per day, with a morning peak and an early evening trough, and is regulated through a negative feedback on the hypothalamus and pituitary.
In the circulation, approximately 98% of testosterone molecules are protein bound. Of this, about one-third are weakly bound to albumin, and the remainder are tightly bound to sex hormone-binding globulin (SHBG). In target cells, testosterone is converted to two active metabolites: dihydrotestosterone (DHT) and estradiol. There is tissue variability in the concentration of the cytoplasmic enzymes required for this conversion, 5 a-reductase and aromatase, respectively, and differential tissue sensitivity to each of these metabolites. Both testosterone and DHT bind to the androgen receptor (AR); estradiol binds to an estrogen receptor. The steroid-receptor complex binds to specific sequences of genomic DNA, which thereby influences messenger RNA production and modulates synthesis of a wide array of enzymatic, structural, and receptor proteins. Testosterone also influences cellular activity in a nongenomic manner through activation of membrane receptors, second messengers, and the membrane itself. Such nongenomic actions appear to be especially important in the CNS.
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A progressive decline in LH and in testosterone occurs in aging men, such that men in the 7th decade have mean plasma testosterone levels that are 35% lower than young men, and more than 25% of men over the age of 75 years appear to be testosterone deficient. 12 The etiology of age-related decline in testosterone level is multifactorial. First, testosterone production is reduced because of a decrease in the number of Leydig cells. Second, diurnal variation -that is, the morning peak in testosterone secretion, is lost in elderly men. 12 Third, the concentration of SHBG increases with age. Since this is the primary testosterone-binding protein, the effect is a steeper age-related decline in free testosterone. 13 Finally, there is some reduction in hypothalamic-pituitary function, with blunted feedback response to low testosterone levels (despite generally high levels of gonadotropins) and to GnRH stimulation. In addition, the normal pulsatile GnRH release is replaced by irregular pulses that are less effective in stimulating LH release from the pituitary. 14 Symptomatic hypogonadism reliably develops when the total testosterone level falls below a certain threshold, assumed by clinical consensus to be between 200 and 300 ng/dl. Standard treatment involves replacement with exogenous testosterone. Multiple placebo-controlled clinical trials (generally in younger men) have demonstrated that testosterone replacement reverses hypogonadal sequelae: body weight, fat-free muscle mass, muscle size and strength increase; continued bone loss is prevented; sexual function and secondary sex characteristics (e.g., facial hair) are restored and maintained; and hematocrit increases. [15] [16] [17] Yet, there are only limited controlled data on the effects of testosterone replacement in elderly men. Placebo-controlled trials in aging men are particularly important, since agerelated decreases in testosterone are generally more modest than the profound hypogonadism studied in testosterone replacement trials in younger men.
HPG-axis and depression
Hypogonadism and mood -clinical studies There appears to be a clinical consensus among andrologists that testosterone replacement enhances mood in hypogonadal men. 18, 19 21 N ¼ 208. In both, investigators demonstrated that compared to hypogonadal baseline, testosterone replacement was associated with improved mood and 'well-being,' and reduced fatigue and irritability. Notably, in one of these clinical trials 22 the investigators continued to follow 123 men on testosterone replacement for 3 years and reported that the improvements in mood persisted. Yet, importantly, no placebo controls (or placebo substitutions) were included in these studies, leaving the question open as to whether the reported mood improvements might have been equally detectable in a placebo group of hypogonadal men who thought they might be receiving testosterone.
Indeed, this negative picture emerges from the only two placebo-controlled testosterone replacement studies in which mood was systematically assessed. 8, 23 In both, despite describing mood as a primary outcome, the results were reported in a limited manner (i.e., one general sentence, no table, graph, or data, as were provided for all other outcomes). In neither was a testosterone-placebo difference distinguishable with respect to mood. For example, Steidle et al. 23 randomized 99 hypogonadal men to placebo and 307 hypogonadal men to different doses of testosterone replacement. Patients rated positive moods (alert, full of energy, friendly, well or good) and negative moods (angry, irritably, sad or blue, tired, nervous) on a 0-7 Likert scale. The one sentence describing the mood results is the following: 'Although all treatments resulted in mean improvements from baseline in both positive and negative mood scores, no significant differences among the treatment groups were observed.' 23 Finally, in a well-designed experiment, Schmidt et al. 24 examined the mood effects of a 1-month suppression of testosterone secretion with leuprolide, followed by double-blind, placebo-controlled testosterone replacement in 31 healthy young men. They demonstrated that overall there was a minimal effect of induced testosterone deficiency on mood, though the testosterone-deficient state was associated with reduced libido and reduced feelings of being 'emotionally charged.' Notably, three men (10%) experienced clinically relevant depressive symptoms during the hypogonadal state, and these were reversed by testosterone replacement.
Hypogonadism and mood -epidemiological studies
Investigators have used population-based studies to examine the relation between testosterone level and depressive symptoms. The Massachusetts Male Aging Study (MMAS) was a community-based sample of men aged 40-70 years (N ¼ 1709). 1, 25 Participants completed a self-report depression inventory, the Center for Epidemiologic Studies Depression Scale (CES-D) and provided a morning blood sample for hormone measurement. In a multiple logistic regression analysis, serum testosterone levels were not associated with CES-Ddiagnosed depression (i.e., CES-DX16; OR 0.90, 95% CI 0.75-1.09). However, in a follow-up analysis of this data, Seidman et al. 26 included data regarding an AR genetic polymorphism. The AR gene has a polymorphic CAG repeat sequence whose length is inversely correlated with transactivation; inverse relations have been described between the number of CAG triplets in the AR gene and androgenmediated processes, such as the risk of prostate cancer. In the MMAS cohort there was a significant interaction between AR CAG repeats, testosterone level, and CES-D, suggesting that these HPG-axis state and trait features may interact to produce depressive symptoms. That is, whereas neither testosterone level nor AR isotype alone were associated with CES-D-defined depression, in a model using all three variables, AR isotype and testosterone together predicted depression (significant effect for the interaction term). 26 Thus, this AR trait marker may define a vulnerable group in whom depression is expressed when testosterone levels fall below a particular threshold. A similar vulnerability based on the interaction of these HPG markers has been described with regard to risk for Alzheimer's disease. 27 In the Rancho Bernardo Study, 28 adult residents of a Southern California community were enrolled in a study of heart disease risk factors. In a 10-year follow-up study that included 82% of the surviving community residents, 856 men aged 50-89 years (mean age, 70 years) completed the Beck Depression Inventory (BDI) and had a morning blood sample drawn for hormone assays. Multiple linear regression analysis revealed a significant inverse correlation between BDI score and bioavailable, but not total, testosterone levels (B ¼ À0.30270.11, P ¼ 0.007). That is, men with lower free testosterone levels had higher BDI scores, which is indicative of increased depressive symptoms.
Depressive disorders and HPG-axis functioning
In most studies that have addressed the HPG-axis in depressed men, there is limited evidence that depressed men -at any age -have significant HPGaxis dysfunction. Neuroendocrine studies of HPGaxis functioning among men with major depressive disorder (MDD) have been cross-sectional, that is, mean testosterone levels in a group of depressed men are compared with a group of non-depressed control subjects; and longitudinal, in which testosterone levels during acute depressive illness are compared in the same men to hormone levels after remission. Findings from such studies have been inconsistent, except for the demonstration that early morning testosterone release is blunted in men with melancholic depression. 29, 30 Overall, comparable numbers of studies have demonstrated lower testosterone levels in depressed men vs controls as have those showing no difference in testosterone levels between depressed vs controls; none have demonstrated higher testosterone levels in the depressed state.
2 Inconsistencies in this literature may be due to small sample sizes, different diagnostic assessments of depression, and heterogeneity in depressive symptoms or diagnoses in different study samples. There is also likely to be considerable diurnal, seasonal, situational, and age-related variability in HPG-axis functioning from study to study. However, data are most consistent with the interpretation that there is virtually no functional effect of MDD on the male HPG-axis.
Some data suggest that the slow, age-related decline in testosterone level, persisting over years, might lead to a chronic, low-grade, depressive illness such as dysthymia, but not to MDD. In a sample of elderly depressed men who presented to a geriatric depression clinic, Seidman et al. 31 demonstrated that the median total testosterone level in 32 men with dysthymia (295 ng/dl; range, 180-520 ng/ dl) was significantly lower than that of 13 agematched men with MDD (425 ng/dl; range, 248-657 ng/dl) or 175 age-matched, 'non-depressed' men from the MMAS sample (423 ng/dl; range, 9-Normative hypogonadism and depression SN Seidman 1021 ng/dl). Notably, 56% of these elderly dysthymic men had testosterone levels in the hypogonadal range (i.e., p300 ng/dl).
In this context, two epidemiological studies provide indirect support for the hypothesis that the testosterone-mood relationship is curvilinear. In a study completed in Belgium, Delhez et al. 32 evaluated morning hormone levels and self-reported psychiatric symptoms in 153 men aged 50-70 years. Using a Carroll rating scale (CRS) for depression, they found that free testosterone was negatively correlated with CRS score (r ¼ À0.17). Yet, when 25 frankly depressed subjects (CRS414) were removed from the analysis, the association was stronger (r ¼ À0.33, Po0.01). In the Veterans' Experience Study, a representative sample of Vietnam-era veterans (mean age, 38 years) were administered the Diagnostic Interview Schedule and provided morning blood samples for testosterone assay. Booth et al. 33 demonstrated that the relation between testosterone level and depression was nonlinear: below 600 ng/dl, men with lower testosterone levels were more likely to be depressed whereas above 600 ng/dl, men with higher testosterone levels were more likely to be depressed.
Exogenous testosterone administration
In 1889, Brown-Sequard reported that self-injections of the extracts of crushed animal testicles were rejuvenating, and improved 'all the functions depending on the power of action of the nervous centers.' 34 Thereafter, thousands of men received exogenous testosterone to reverse senescence. Although many of these treatments could not have been endocrinologically active, men who received them routinely reported improved energy and mood. In more recent years, some controlled studies -but mostly 'clinical lore' -have been used to support exogenous testosterone as an antidepressant treatment. Yet, overall, mood effects of testosterone appear to be variable.
Non-depressed men
In most clinical trials in which exogenous testosterone was administered to non-depressed eugonadal men at physiological doses, significant effects on mood were not detected. For example, Tricker et al. 35 randomized 43 eugonadal men aged 19-40 years to double-blind treatment with either testosterone or placebo injections weekly for 10 weeks; they found no change in self-or observer-reported measures of hostility, anger, or mood during testosterone treatment. Matsumoto 36 administered testosterone 100 mg and testosterone 300 mg weekly for 6 months to 20 young eugonadal men, and Janowsky et al. 37 randomized 56 elderly men to receive testosterone or placebo patches for 3 months. In both studies, there were no differences between testosterone and placebo groups in self-reported measures of mood. Administration of supraphysiological doses of testosterone to eugonadal men has been associated with mania in a small proportion of men. For example, Yates et al. 38 administered testosterone (100, 250 or 500 mg per week) for 14 weeks to 18 men; one (6%) became manic. Su et al. 39 administered methyltestosterone or placebo for a short time (3 days of 40 mg/day then 3 days of 240 mg/day) to 20 eugonadal men; one man became manic and one hypomanic. Notably, overall change in aggressiveness (anger, violent feelings, and irritability) was correlated with the change in free T4 (r ¼ 0.5, P ¼ 0.02); changes in total testosterone correlated only with changes in cognitive functions (forgetfulness, distractibility) (r ¼ 0.52, P ¼ 0.02). 40 Pope et al. 41 randomized 66 men (age range 20-50 years) who did not have psychiatric histories to receive testosterone in doses rising to 600 mg per week, or placebo, for 6 weeks, followed by a 6-week no treatment period, and then crossover to the alternate treatment. They found that testosterone administration significantly increased the mean manic score on the Young Manic Rating Scale (YMRS) (P ¼ 0.003) and on daily diaries (P ¼ 0.004), the 'like the way I feel' score on daily diaries (P ¼ 0.01), and aggressive responses on the Point Subtraction Aggression Paradigm (PSAP) (P ¼ 0.04).
Non-depressed men with sexual dysfunction
There are some well-controlled studies of testosterone administration to eugonadal men with sexual dysfunction. [42] [43] [44] In general, they have demonstrated that administration of physiologic doses of testosterone: (1) is no more effective than placebo for ED, (2) leads to a modest increase in sexual interest and (3) does not lead to a change on self-report measures of mood. For example, Schiavi et al. 42 enrolled 18 eugonadal men (age range 46-67 years) who presented with the chief complaint of ED in a double-blind, placebo-controlled, crossover study of testosterone 200 mg or placebo every 2 weeks for 6 weeks. They found that during the testosterone compared to placebo phase: ejaculatory frequency doubled; other measures of sexual arousal increased, but this was not statistically significant; erectile function and sexual satisfaction were unaffected; and mood, assessed by self-report instruments, was unaffected. 42 Most subjects could not correctly identify the phase in which they received testosterone, and felt it was not helpful. Notably, the authors were unable to demonstrate that this schedule of testosterone administration led to an increase in circulating levels 2 weeks after each Normative hypogonadism and depression SN Seidman intramuscular injection -suggesting that this dose may have been too low to over-ride the compensatory feedback mechanisms operating in eugonadal men. O'Carroll and Bancroft 44 administered testosterone to men with ED (n ¼ 10) and hypoactive sexual desire (n ¼ 10). There was no demonstrable effect of testosterone on erectile function, and a clinically significant effect on desire in only 3 patients in the low-desire group. Carani et al. 45 2), which measures the extent to which an individual seeks sexual stimuli. There was no effect on measures of sexual behavior, including intercourse frequency, erectile function, or masturbation and no apparent effect on mood. Overall, the data suggest that in eugonadal men, exogenous androgen treatment has no effect on ED but may help hypoactive desire. In hypogonadal men, androgen replacement clearly improves desire and some aspects of erectile functioning. It is not known whether mild, age-related HPG hypofunctioning is associated with any sexual dysfunction, and if it is, whether androgen replacement is effective.
Depressed men
Reports from the older psychiatric literature on the 'antidepressant' effects of testosterone suggested that a substantial number of 'depressed' men responded immediately and dramatically to hormone replacement therapy and subsequently relapsed when treatment was discontinued. 47 However, standardized, syndromal, psychiatric diagnoses were not used in these studies, and baseline testosterone levels were not assessed. Moreover, the lack of a control group limits interpretation of the results.
More recent anecdotal reports have suggested that in some hypogonadal men, comorbid MDD remits with testosterone replacement [48] [49] [50] or augmentation to partially effective antidepressant, 51 and that in hypogonadal, HIV-infected men, testosterone replacement is associated with improved mood, libido and energy. 52, 53 Based on such reports, it had been assumed that testosterone replacement of hypogonadal men with MDD would conform to the 'hypothyroid' model, that is, hormone axis normalization as an effective antidepressant. Systematic study suggests that this is not generally the case.
Three recent placebo-controlled clinical trials have assessed the potential of exogenous testosterone as an antidepressant treatment. In a doubleblind randomized clinical trial of testosterone replacement versus placebo in 30 men with MDD and testosterone levels of 350 ng/dl or less, Seidman et al. 54 found testosterone replacement indistinguishable from placebo: 38% responded to testosterone, and 41% responded to placebo. Pope et al. 55 conducted a randomized trial of testosterone or placebo gel supplementation in 22 men with medication-resistant MDD and testosterone levels of 350 ng/dl or less. Men who received testosterone gel improved significantly more than those who received placebo gel on the HAM-D (Po0.001). Finally, Seidman et al. 56 recently reported that in 26 eugonadal men with medication-resistant MDD, supplementation with testosterone or placebo were indistinguishable.
In summary, there is limited evidence that exogenous androgen treatment has antidepressant effects in some male depressives. Such effects may be more prominent among men who are hypogonadal, though this is not well established. In general, the evidence is too limited to evaluate whether the mood effects of exogenous testosterone are related to testosterone replacement, symptomatic improvement (e.g., increased libido or energy), or nonspecific placebo effects. Currently, use of testosterone as replacement (i.e., in hypogonadism) or as an antidepressant augmentation in men with depression should be considered experimental.
Exogenous testosterone: clinical considerations
Exogenous testosterone, even at supraphysiological doses, rarely produces side effects, though there is a remote risk of developing gynecomastia (i.e., breast tenderness and breast enlargement), truncal acne (particularly for those with a history of acne), hair loss or hair growth, and/or weight gain; there is always a modest increase in hematocrit. 57, 58 Via the negative feedback mechanism, exogenous testosterone suppresses LH and FSH which leads to reduced testicular sperm production and, consequently, reduced testicular volume.
The primary concern regarding potential adverse effects of testosterone treatment is on the prostate. Androgens play a permissive role in the development of prostate cancer and benign prostate hyperplasia; however, there are no data to indicate that testosterone administration can lead to the progression of pre-clinical or clinical prostate cancer. 57, 58 All patients should have a pre-treatment PSAo4.0, a normal digital rectal exam of the prostate, and a normal hematocrit. Finally, a history of breast or prostate cancer is an absolute contraindication to treatment with exogenous testosterone. 57, 58 Normative hypogonadism and depression SN Seidman T levels p300 ng/dl T gel 50 or 100 mg/daily; T patch 2.5 mg/day; PBO gel; for 3 months All doses of T and PBO associated with significantly improved positive and negative mood from baseline; no betweengroup differences Pope et al. 
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Conclusion
Delineation of the role of the HPG-axis in the psychiatric problems of male aging may be of substantial public health importance. The psychiatric sequelae of age-related female gonadal hypofunction (i.e., menopause) are well characterized and substantial. Such knowledge has led to productive therapeutics research. There is no parallel characterization of the psychophysiology of agerelated male hypogonadism, despite important implications for the treatment of psychiatric problems in this population. For example, the suicide rate in elderly white males triples from the sixth decade to the ninth decade; in comparable women, it remains unchanged after age 40 years. 59 Further research is necessary to determine whether age-associated, male-specific mood problems are related to untreated, 'normative' hypogonadism (Table 1) .
